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A B S T R A C T
Dandruﬀ is a common condition, aﬀecting up to half the global population of immunocompetent adults at some
time during their lives and it has been highly correlated with the over-expression of the fungus Malassezia spp.
Climbazole (CBZ) is used as an antifungal and preservative agent in many marketed formulations for the
treatment of dandruﬀ. While the eﬃcacy of CBZ in vitro and in vivo has previously been reported, limited in-
formation has been published about the uptake and deposition of CBZ in the skin. Hence, our aim was to
investigate the skin permeation of CBZ as well as the inﬂuence of various solvents on CBZ skin delivery. Four
solvents were selected for the permeability studies of CBZ, namely propylene glycol (PG), octyl salicylate (OSal),
Transcutol® P (TC) and polyethylene glycol 200 (PEG). The criteria for selection were based on their wide use as
excipients in commercial formulations, their potential to act as skin penetration enhancers and their favourable
safety proﬁles. 1% (w/v) solutions of CBZ were applied under inﬁnite and ﬁnite dose conditions using Franz type
diﬀusion cells to human and porcine skin. In line with the topical use of CBZ as an antidandruﬀ agent, com-
paratively low amounts of CBZ penetrated across the skin barrier (< 1% of the applied dose of CBZ). Finite dose
studies resulted in a higher extraction of CBZ from human skin compared with inﬁnite dose studies (p < 0.05).
CBZ was also taken up to a higher extent in porcine skin (> 7-fold) compared with human skin (p < 0.05).
Nevertheless, no statistical diﬀerences were observed in the amounts that permeated across the diﬀerent
membranes. These preliminary results conﬁrm the potential of simple formulations of CBZ to target the outer
layers of the epidermis. The PG and OSal formulations appear to be promising vehicles for CBZ in terms of
overall skin extraction and penetration. Future work will expand the range of vehicles studied and explore the
reasons underlying the retention of CBZ in the outer layers of the skin.
1. Introduction
Human skin is a formidable barrier protecting against the entry of
foreign substances and preventing excessive water loss from the body
(Hadgraft and Lane, 2005; Notman and Anwar, 2013; Proksch et al.,
2008). Notwithstanding this, various formulation approaches have
been developed to overcome the skin’s inherent resistance to penetra-
tion of actives. Topical and transdermal delivery of drugs is also at-
tractive compared with oral or intravenous administration, as ﬁrst pass
metabolism is avoided and patient compliance when using such for-
mulations is generally higher (Zorec et al., 2013). Many diseases re-
quire the active to be targeted to the skin itself. This is the case for
many antifungals used to treat skin infections, where the oral route
would require comparatively high doses of drugs and may result in
undesirable systemic eﬀects (Glujoy et al., 2014).
Dandruﬀ is a common scalp disorder causing excessive scaling of the
scalp and impaired skin barrier function (Hay, 2011). The commensal
fungus Malassezia spp is commonly found in the scalp, but excessive
proliferation of this organism is highly correlated with the presence of
dandruﬀ (DeAngelis et al., 2005). Dandruﬀ is generally treated using
medicated shampoos incorporating one or more actives to target dif-
ferent stages of the condition. These shampoos can contain keratolytic
agents (salicylic acid, sulfur), regulators of keratinisation (zinc, tar,
steroids), antimicrobial agents (selenium sulphide, imidazole anti-
fungals, hydroxypyridones) and naturopathic remedies (tea tree oil)
(Piérard et al., 2000; Sanﬁlippo, 2006).
Climbazole (CBZ) is an imidazole antifungal agent used to manage
dandruﬀ in formulations such as shampoos or conditioners and as a
preservative (Fig. 1). It has a molecular weight of 292.8 gmol−1 and a
reported melting point of 95–97 °C and it acts by inhibiting the synth-
esis of ergosterol, a major component in fungal plasma membranes
(SCCP, 2009). In addition, CBZ has been shown to upregulate kerati-
nocyte diﬀerentiation promoting the expression of small-proline-rich
proteins in primary keratinocytes (Pople et al., 2014). Bhogal et al.
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(2014) also reported inhibitory eﬀects of CBZ on hair proteases in-
volved in anchorage of the hair shaft in an in vitro study.
Ideally, formulations of CBZ should target the molecule to the
stratum corneum and/or the hair follicles, for local eﬀects on scalp mi-
crobiota. The minimum inhibitory concentration (MIC) for CBZ for
various species of Malassezia associated with dandruﬀ ranges from 125
to 62.5 µgml−1 (M. globosa=M. restricta > M. furfur) as reported by
Gokulshankar et al. (2011). Lower MICs have been reported by Youn
et al. (2016), in the order of 1–2 µgml−1, showing a higher antifungal
eﬃcacy of CBZ compared with piroctone olamine, another antifungal
agent used for the treatment of dandruﬀ. Various authors have reported
the in vitro activity and associated clinical outcomes of CBZ in the lit-
erature (Chen et al., 2015; Schmidt-Rose et al., 2011; Youn et al., 2016).
Garrett et al. (2017) also investigated the deposition of CBZ and zinc
pyrithione in porcine skin with stimulated Raman scattering micro-
scopy. Higher penetration of CBZ into the hair shaft was observed
compared with zinc pyrithione, the latter compound being deposited as
crystals on the skin surface because of its lower lipid solubility. How-
ever, there is still limited information detailing skin delivery or eﬃ-
ciency of CBZ following topical application. As the molecule has a
comparatively low melting point, low molecular weight and is lipo-
philic with a predicted log Po/w of 3.76 (SCCP, 2009), these properties
suggest it is a suitable permeant for delivery to the skin (Hadgraft,
2004). The aim of the present work was to investigate the topical de-
livery of CBZ from four solvents. These vehicles were selected based on
their solubility parameters, their application as skin penetration en-
hancers in other formulations, and their favourable safety proﬁles
(Haque et al., 2017; Santos et al., 2010). Permeation and mass balance
studies were conducted under inﬁnite and ﬁnite dose conditions. Por-
cine ear skin has previously been proposed as an appropriate surrogate
model for human scalp skin (Rolland et al., 2011). A secondary objec-
tive of the present work was, therefore, to investigate the diﬀerences in
CBZ uptake and delivery in porcine and human tissues.
2. Materials and methods
2.1. Materials
Climbazole (Crinipan® AD, Symrise, Germany) was supplied by
Unilever (Port Sunlight, UK). Propylene glycol (PG), polyethylene
glycol 200 (PEG), 2-ethylhexyl salicylate (OSal) and 1,2-pentanediol,
were purchased from Sigma Aldrich, UK. Transcutol® P (TC) was a gift
from Gattefossé, France. HPLC grade water, acetonitrile (ACN) and
methanol, 1,2-isopropanol, absolute ethanol (EtOH), sodium di-hy-
drogen orthophosphate, di-sodium hydrogen orthophosphate and di-
methyl sulfoxide (DMSO) were purchased from Fisher Scientiﬁc, UK.
For the permeation studies, phosphate buﬀered saline (PBS) tablets (pH
7.3 ± 0.2 at 25 °C) were supplied by Oxoid Limited, UK. High-vacuum
grease was purchased from Dow Corning, Belgium and sodium azide
was obtained from Fluka, Sigma Aldrich, UK. Full thickness porcine ear
skin was obtained from a local abattoir as the waste product from pig
carcasses that had been slaughtered the same day for food chain pur-
poses. The full thickness skin was separated from the cartilaginous
tissue at room temperature and then stored at −20 °C for short time
until needed. Abdominal human skin was obtained following plastic
surgery from a single female donor with institutional ethical approval
and informed consent, provided by Ethical Tissue (Research Ethics
Committee reference 07/H1306/98). The human skin was stored at
−20 °C before use and the epidermis was heat separated before the
studies as reported previously (Oliveira et al., 2012).
2.2. Melting point calculation
A Tzero™ press (TA instruments, USA) was used to seal the pan
containing CBZ hermetically with its corresponding lid (TA instru-
ments, USA) and an empty pan sealed with its lid was used as the re-
ference. The samples were then heated from −20 to 140 °C at
10 °Cmin−1 under N2 gas (50mlmin−1) in a diﬀerential scanning ca-
lorimeter Q2000, (TA Instruments, USA). Data analysis was performed
with TA Universal Analysis software.
2.3. Log Po/w, Log Do/w and solubility determination
The Log Po/w was calculated with Molecular Modelling Pro®
(Version 6.3.3) software (ChemSW, CA, USA). The Log Do/w for CBZ
was determined experimentally using the shake ﬂask method (OECD,
1995). Experiments were conducted at pH 5.0, 7.3 and 9.0 using a citric
acid/trisodium citrate buﬀer, PBS tablets and sodium carbonate/so-
dium bicarbonate for the respective buﬀer solutions. N-octanol was
used as the organic phase. All experiments were performed at room
temperature (23 ± 2 °C). The amount of active in each phase in the
diﬀerent ratios was determined using HPLC to calculate the log Do/w as
shown in Equation (1), where Cn–octanol is the concentration in the or-








log logow n - octanol
aqueous (1)
An excess amount of added to 0.5 ml of solvent with stirring bars in
ﬂat bottom tubes. Tubes were capped, covered with Paraﬁlm® (Bemis
Company Inc., USA) and placed in a JB Nova thermostatically con-
trolled water bath (Grant, UK) equipped with a HP 15 stirring system
(Variomag®, USA) at 32° ± 1 °C for 48 h. The tubes were centrifuged at
13,200 rpm for 30min at 32 °C, the supernatant was then carefully
withdrawn and suitably diluted where necessary for analysis by HPLC.
All measurements were conducted in triplicate.
2.4. Dynamic vapour sorption studies
A dynamic vapour sorption (DVS) apparatus (Surface Measurement
Systems, UK) was used to study the mass diﬀerences resulting from
evaporation or hydration of the candidate formulations. 15mm quartz
glass pans (reference and sample) connected to a microbalance accurate
to 0.0001mg were used to evaluate the mass variations. Temperature
and relative humidity (RH) were controlled throughout the experiment
at 32 ± 1 °C and 50 ± 2% RH, respectively. The DVS instrument was
calibrated with a 100mg weight and 10 µl of formulation was placed on
the sample chamber for 24 h, i.e. solutions of 1% CBZ (w/v) in PG,
OSal, TC and PEG 200. Data were recorded in 10 s intervals using
DVSWin V3.01 (Surface Measurement System, UK).
2.5. Permeation studies
According to the current guidelines for topical use of CBZ in humans
(SCCP, 2009), a concentration of up to 2% (w/v) in rinse-oﬀ hair
products is allowed, and thus this concentration of active was used as a
guide for in vitro studies. Initially, inﬁnite dose studies were performed
in human and porcine ear skin, followed by ﬁnite dose studies. In all
cases, 1% (w/v) CBZ solutions in propylene glycol (PG), octyl salicylate
(OSal), polyethylene glycol 200 (PEG) and Transcutol® P (TC) were
applied to the membranes. 250 µl per cm2 of skin surface were applied
Cl  
Fig. 1. Chemical structure of climbazole.
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for inﬁnite dose studies while ∼10 µl cm−2 of the formulation were
applied for ﬁnite doses using a positive displacement pipette (Eppen-
dorf®, UK), as described elsewhere (OECD, 2004b). Sink conditions
were maintained throughout the experiments (Pellett et al., 1997). The
permeation studies were performed using Franz type diﬀusion cells
with a diﬀusion area of ∼1 cm2, accurately measured, as reported
previously (Santos et al., 2010). Experiments were conducted for 48 h
for the inﬁnite dose studies and 24 h for the ﬁnite dose studies in a JB
Nova thermostatically controlled water bath (Grant, UK) equipped with
a HP 15 stirring system (Variomag®, USA). The upper surface tem-
perature of the membrane was kept at 32 ± 1 °C. Samples were col-
lected at 0, 8, 24 and 48 h for the inﬁnite dose studies and 0, 8, 20 and
24 h for ﬁnite dose studies. 200 µl of receptor phase were withdrawn for
each sample and the same volume of fresh PBS was replaced im-
mediately after sample collection.
2.6. Mass balance studies
Both skin washing and extraction procedures were validated to
conﬁrm the recovery of the active was within the accepted ranges
(OECD, 2004b). After the 24 or 48 h permeation studies (ﬁnite and
inﬁnite dose studies, respectively), the remaining volume in the donor
(inﬁnite dose studies) was removed and diluted accordingly to allow
HPLC analysis. The surface of the skin was then washed with 1ml of
absolute ethanol (EtOH) four times for each cell in order to clean the
surface of the skin thoroughly whilst avoiding extraction. The diﬀusion
cells were disassembled, and the skin was placed in 2ml microtest tubes
(Eppendorf®, UK) for extraction with 1ml of DMSO in a temperature-
controlled oven at 32 ± 1 °C (Jouan Series Thermo Fisher Scientiﬁc,
USA). After 24 h rotation in the oven, two 15min cycles of sonication
(Ultrasonic Cleaner USC-THD VWR International, USA) and cen-
trifugation at 13,200 rpm (5415 R centrifuge Eppendorf®, UK) were
performed. Following suitable dilution, the remaining volume in the
donor, washings and the extraction supernatants were analysed by
HPLC.
2.7. HPLC analysis
HPLC analysis was performed using an Agilent HPLC (Agilent 1100
series, USA) and a reverse phase C18 column (Kinetex 5 µm, pore size
100 Å, 50 x 4.6mm; Phenomenex, UK). The mobile phase was phos-
phate buﬀer pH 7.4 ± 0.2 : Acetonitrile (40:60). The column tem-
perature, mobile phase ﬂow rate and injection volume were set at 30 °C,
1mlmin−1 and 10 µl, respectively. The detection wavelength was set to
220 nm. Validation of the method was conducted according to ICH
Guideline (2005). Calibration curves were prepared in ethanol and
linearity was observed within the concentration range of
0.24–50 µgmL−1 (r2≥ 0.99). The limit of detection was 0.49 µgml−1
and the limit of quantiﬁcation was 1.49 µgml−1. As previously reported
(Parisi et al., 2016) and described by Keizer et al. (2015), the values
within LOD and LOQ were treated the same as the values above LOQ,
while the measurements below the LOD were considered inaccurate
and therefore were noted as not detected.
2.8. Statistical analysis
Data were plotted using Microsoft® Excel (Microsoft, USA) and
GraphPad Prism® (Graphpad software, USA). The statistical analysis
was carried out using SPSS® Statistics Version 22 (IBM, USA). The re-
sults were assessed for normality using the Shapiro-Wilk Test, and the
homogeneity of variance was assessed using Levene's test. One-way
ANOVA and Independent samples t-test were performed where appro-
priate. Multiple comparison Tukey’s HSD post hoc test was used after
ANOVA analysis to perform pairwise analysis. For non-normally dis-
tributed data or where variances were not equal, the Kruskal-Wallis and
Mann-Whitney U Tests and independent sample t-test were used,
respectively. A p-value lower than 0.05 (p < 0.05) was considered
statistically signiﬁcant.
3. Results and discussion
3.1. Thermal analysis
The onset temperature of the melting point and the enthalpy of
fusion were determined to be 96.68 °C and 29.63 kJmol−1, respectively
as shown in Fig. 2. One single endothermic event in the DSC curve
allowed identiﬁcation of the pure compound, with no impurities or
polymorphism evident. Although these results diﬀer from the corre-
sponding values of 98.85 °C and 29.0 kJmol−1 reported for CBZ by Kim
et al. (2014), this is likely to reﬂect the diﬀerent grades of CBZ available
from various suppliers.
3.2. Log Po/w, Log Do/w and solubility studies
The predicted value for the Log Po/w of CBZ is 3.01 and experi-
mentally determined distribution coeﬃcients (Log Do/w) are reported in
Table 1. A signiﬁcantly lower Log Do/w is evident at more acidic pH
values. Since this molecule is a weak base (pKa= 7.51), the imidazole
group will be ionized to a greater extent at lower pH values. Hence, a
higher aﬃnity for the aqueous phase is expected, yielding a lower log
Do/w. In basic solutions (pH values of 7.3 and 9), no diﬀerences in the
log Do/w were observed (ANOVA, p= 1) but the value was signiﬁcantly
lower at pH 5 (ANOVA, p < 0.001).
The solubility of CBZ was evaluated at 32 ± 1 °C and the results are
shown in Table 2. The high solubility of the molecule in PG and PEG is
consistent with previous reports of the use of these solvents to solubilise
azoles (Kovács et al., 2009; Paradkar et al., 2015) and their inclusion in
several commercially available solution and gel formulations (Willems
et al., 2001). The data also conﬁrm that TC is an excellent cosolvent for
CBZ. Despite the lipophilic nature of the molecule, solubility in OSal
was comparatively lower than for all other solvents.
Fig. 2. DSC analysis of CBZ.
Table 1
Log Do/w values of CBZ at pH values 5.0, 7.4
and 9.0. n= 3, mean ± SD. *= p < 0.01.
pH Log D(o/w)
5 2.83 ± 0.02*
7.3 3.20 ± 0.03
9 3.20 ± 0.02
M. Paz-Alvarez et al. International Journal of Pharmaceutics 549 (2018) 317–324
319
Solubility studies were also conducted in ethanol and DMSO. High
CBZ solubility was observed in ethanol (> 0.8 g/ml), in line with
published data (Kim et al., 2014). CBZ also showed high solubility
values in dimethyl sulfoxide (DMSO), with values> 1.0 g/ml. These
results also conﬁrmed the suitability of these solvents for the extraction
and surface cleaning procedures in mass balance studies.
3.3. DVS results
Fig. 3 shows the DVS results for all CBZ solutions over the time
course of the permeation studies (24 h) at 32 ± 1 °C and 50 ± 2% RH.
Although the PG and TC formulations showed an initial increase in
weight because of their hygroscopic nature, the solvents evaporated
over time, consistent with the evaporation of neat PG and TC reported
in our previous study (Haque et al., 2017). No mass changes were
evident for the PEG and OSal formulations; to our knowledge DVS has
not been used previously to characterise the behaviour of these solvents
under controlled conditions of temperature and humidity.
Fig. 4 shows the percentage recovery of CBZ from the skin surface,
extracted from the skin and any recovery in the receptor ﬂuid. For both
inﬁnite and ﬁnite dose applications 1% (w/v) CBZ was applied; the
respective volumes were 250 µl and 10 µl for inﬁnite and ﬁnite dose
experiments. The overall recoveries were within the acceptable range of
80%-120% (OECD, 2004a). Acceptable overall recovery of the active
during mass balance studies conﬁrmed that CBZ was stable during the
course of the permeation and sample analysis time. The stability of the
formulations was also assessed during preformulation studies to ensure
no degradation was observed up to 4 days as shown in Fig. A.1 in the
tested formulations and PBS.
CBZ acts as an antidandruﬀ agent by preventing the synthesis of
ergosterol in fungal cells, acting primarily in the superﬁcial layers of the
stratum corneum, where the fungus is mainly located (Piérard-
Franchimont et al., 2006). Therefore, an optimal formulation would
deliver the active speciﬁcally to the skin, minimising transdermal de-
livery to avoid systemic levels. The key parameter to be considered for
the eﬀective topical delivery of CBZ is therefore the amount extracted
from the membrane. Three of the four vehicles delivered higher per-
centages (p < 0.05) of CBZ into the skin samples for the ﬁnite dose
studies (Fig. 4B), when compared with inﬁnite dose studies (Fig. 4A). In
absolute amounts, inﬁnite doses of CBZ in PG delivered 4.6 ± 0.6 µg to
the membrane compared with 1.5 ± 0.5 µg for ﬁnite dose studies, i.e,
0.18 ± 0.03% versus 1.4 ± 0.5% from the applied doses, respectively.
Therefore, absolute amounts delivered to the membrane were higher
from the inﬁnite doses, but the relative amounts recovered were higher
for ﬁnite dose studies. Similarly, recovery of CBZ from the OSal vehicle
was 2.5 ± 0.8 µg for inﬁnite doses compared with 0.9 ± 0.4 µg for
ﬁnite doses. For the TC vehicle, the amount of CBZ extracted from the
skin was 0.5 ± 0.2 µg for the inﬁnite dose compared with
1.2 ± 0.6 µg for the ﬁnite dose studies.
The DVS results indicate that PG and TC will evaporate from the
ﬁnite dose studies to a much greater extent than the inﬁnite dose stu-
dies. Therefore, the thermodynamic activity of CBZ will also change
much more rapidly when applied in ﬁnite versus inﬁnite doses. The
depletion of vehicles because of evaporation has also been reported to
have a marked eﬀect on skin permeation and uptake of actives (Selzer
et al., 2013). Oliveira et al. (2012) have also reported the use of volatile
solvents to increase the permeability of methyl paraben. The surface
tension of the solvents in the formulation along with the small amounts
applied can hinder the uniform spreading of the preparation on the skin
Table 2
Solubility of CBZ at 32 ± 1 °C in TC, PEG 200, PG, OSal (n=4, mean ± SD)
and Log Po/w values of TC, PEG 200, PG and OSal extracted from the literature.
Solvent CBZ solubility (mg ml−1) Log Po/w
TC 422.4 ± 4.9 −0.25†
PEG 276.3 ± 5.6 −0.93††
PG 273.3 ± 8.8 −0.47†
OSal 39.0 ± 2.1 5.97†††
† (Haque et al., 2017).
†† (Oliveira et al., 2012).
††† (Santos et al., 2010).
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Fig. 3. Percentage of weight loss from 1% CBZ solutions in PG, TC, OSal and
PEG as prepared for inﬁnite and ﬁnite permeation studies. n= 3, mean ± SD.
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Fig. 4. Percentage of CBZ recovered from applied dose after mass balance in
human epidermis for (A) inﬁnite dose application of 1% (w/v) CBZ in PG, OSal,
PEG and TC and (B) ﬁnite dose application of 1% (w/v) CBZ in PG, OSal, PEG
and TC. 4≤ n≤ 7, mean ± SD.
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(van de Sandt et al., 2004). Even though the small volumes were dis-
tributed with a plastic inoculating loop, the formulation tended to form
droplets on the surface after some time, leading to higher variability
observed in the permeation and extraction values characteristic of ﬁnite
dose studies. These diﬀerences have also been reported by Selzer et al.
(2013), who highlighted the diﬃculties in measurements for ﬁnite dose
studies.
Although inﬁnite dose studies allow the calculation of steady-state
permeation parameters, the results reported here conﬁrm that results
from such studies may not be extrapolated to ﬁnite dose studies that
better simulate “real-life” use of topical preparations. As we have noted
previously, for prediction of formulation eﬃciency and selection of
appropriate solvents, ﬁnite dose studies must be preferred over inﬁnite
dose conditions (Lane, 2013).
When the recovered amounts of CBZ in the receptor phase were
compared between ﬁnite and inﬁnite dose experiments, no statistical
diﬀerences were found (p > 0.05). The relatively low permeation of
CBZ for both inﬁnite and ﬁnite dose studies is surprising because, as
noted above, the molecule has favourable physicochemical properties
for dermal penetration. Fig. 4 shows that CBZ only permeated through
the skin from the PG and OSal formulations and permeation was evi-
dent only after 20 h. The recovered amounts of CBZ were very low and
close to the limit of detection. The reasons for the low permeability of
CBZ remain to be elucidated, although keratin binding has been re-
ported for other members of the imidazole family including omocona-
zole, bifonazole and clotrimazole (Hashiguchi et al., 1998).
3.4. Comparison of permeation and mass balance studies in human skin and
porcine skin
Results for the permeation and mass balance studies in human and
porcine skin are shown in Fig. 5. The percentage of CBZ extracted from
porcine skin was statistically higher for PG (p= 0.058), OSal
(p < 0.01) and TC (p < 0.01) compared with human skin, while it
was not statistically diﬀerent for PEG (p > 0.05). On the other hand,
the permeation values for the applied dose were in all cases not sta-
tistically diﬀerent (p > 0.05). Porcine skin is generally regarded as
more permeable than human skin, and many comparative studies have
been reported in the literature. Many of these have been summarised in
a comprehensive review by Barbero and Frasch (2009). These authors
reported the permeability of 26 diﬀerent chemicals in human and pig
skin and a correlation coeﬃcient (r) of 0.88 (p < 0.0001) was ob-
tained, suggesting that pig skin is an acceptable surrogate for human
skin for the compounds evaluated. The factor of diﬀerence (FOD) was
for 80% of the measurements 0.3 > FOD > 3, which represents a
good prediction. However, in most cases the factor of diﬀerence be-
tween both surrogates was higher than one, indicating that porcine skin
generally yields an over prediction compared with human skin. This
observation was also reported by Dick and Scott (1992), Singh et al.
(2002) and Luo et al. (2016) for mannitol and paraquat, hydrocarbon
structures (heptane, hexadecane, xylene) and ibuprofen, respectively.
This further suggests that CBZ may be binding or “stranded” in the skin,
despite its suitable properties for percutaneous penetration.
The PG solutions were the most eﬀective formulations in porcine
skin (p < 0.01) but not in human skin (p > 0.05). PG solutions de-
livered 1.5 ± 0.5 µg of CBZ to human skin compared with
10.9 ± 1.9 µg for porcine skin. PG has been used as a cosolvent and
penetration enhancer in a range of topical formulations (Trottet et al.,
2004; Duracher et al., 2009; Lane, 2013). Although its enhancing me-
chanism has not been fully elucidated, it has been suggested that the
molecule may intercalate between the polar heads of the lipid lamellae
of the stratum corneum, increasing the gaps in the lipid bilayers and
consequently enabling a higher ﬂux (Brinkmann and Muller-Goymann,
2005; Lane, 2013). TC and OSal delivered approximately half of the
relative amounts of CBZ to the skin compared with PG. Both TC and
OSal have also been used as penetration enhancers in skin formulations
but have been reported to have diﬀerent mechanisms of action (Lane,
2013). OSal is a lipophilic solvent and the residence time of the solvent
in skin is much longer than that for hydrophilic compounds such as PG
(Santos et al., 2011). The ability of TC to act as a penetration enhancer
was previously ascribed to the faster and greater skin penetration of this
molecule compared with other solvents (Haque et al., 2017).
The porcine skin used in this study included epidermal and dermal
layers while heat-separated human skin only comprises epidermal
tissue. Although this diﬀerence in skin thickness may contribute to the
higher relative skin extraction values for CBZ in porcine skin, there are
conﬂicting reports in the literature. Vallet et al. (2007) studied the
permeation of pesticides in split-thickness and full thickness samples for
both human and porcine skin. No statistical diﬀerences were observed
in the overall amounts of the compounds extracted from the various
skin samples. In contrast, there was a statistical diﬀerence (p= 0.04) in
human skin penetration rates compared with porcine skin. Similarly, no
diﬀerences were observed for the ﬂux values of caﬀeine following ap-
plication to dermatomed skin (500 µm) and heat separated epidermis
(Atrux-Tallau et al., 2007). Diﬀerences in the histological structures of
porcine and human skin and the interaction of the active with these
membranes should also be considered when accounting for the higher
extraction of CBZ from porcine skin compared with human skin. The
size of hair follicles in porcine skin has been reported to be nearly twice
that in human skin, being 177 ± 4 and 97 ± 3 µm, respectively
(Jacobi et al., 2007). Taking into account the favourable conditions for
hydrophilic and high molecular weight compounds to permeate across
hair follicles (Mitragotri, 2003), the appendageal pathway (including
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Fig. 5. Percentage of CBZ recovered from applied dose after mass balance in (A)
abdominal human skin ﬁnite dose application of 1% (w/v) CBZ in PG, OSal,
PEG and TC (B) porcine ear skin ﬁnite dose application of 1% (w/v) CBZ in PG,
OSal, PEG and TC. 4≤ n≤ 8, mean ± SD.
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hair follicles and sweat glands) may explain why both models can un-
iquely interact according to the chemistry of the permeant. Diﬀerences
in the molecular structure of both human and porcine skin have also
been studied. (Greve et al., 2008) showed by using a combination of
near-FT-Raman, FT-NIR and ATR-FTIR, that human skin in vivo pre-
sented higher lipid content and lower water mass than its porcine
counterpart. The lipid content of the SC has also been investigated over
the years, showing a diﬀerent composition in human than porcine skin,
more speciﬁcally on the ceramides chain length and fatty acid com-
position (Mojumdar et al., 2014; Wertz et al., 1985). Moreover, the
diﬀerent lipid lamellar structures of human skin compared with porcine
skin might also explain the diﬀerences observed. It has been reported
that human skin has an orthogonal lipid lamellar structure whereas
porcine skin lipids have a hexagonal, more ﬂuid lamellar structure
(Caussin et al., 2008). A more ﬂuid lipid structure could theoretically
lead to higher values of uptake and / or permeation of the active. More
recently, (Choe et al., 2018) used Confocal Raman microscopy to study
the diﬀerences between human and porcine skin. Results showed higher
hydrogen bonding of water in human skin, consistent with higher NMF
concentrations, as well as a more folded structure of keratin in porcine
skin, which could explain a higher permeability of porcine skin.
The permeability of human and porcine skin appears to vary de-
pending on the molecule of interest, and so does the uptake from the
membrane. This is clearly the case for CBZ, where statistically higher
amounts were extracted from the membrane, but similar values of
permeation were reported. As noted, further studies are needed to ex-
amine these ﬁndings including any possibility of keratin binding or
other interaction with the skin.
4. Conclusions
To our knowledge this is the ﬁrst study that has examined skin
uptake and permeation properties of CBZ in porcine and human skin.
Even though CBZ has appropriate physicochemical properties for
dermal penetration, no permeation was observed for some vehicles and
where CBZ could be detected in the receptor compartment, the amounts
recovered were very low. This is surprising when the physicochemical
properties of CBZ are compared with those of ibuprofen, a known skin
permeant. Both actives have molecular weights< 300 Da, melting
points< 100 °C and Log P and Log D values that favour percutaneous
delivery. As reported for other antifungal imidazoles, this may reﬂect
an interaction of CBZ with the keratin of the stratum corneum. Skin
retention of CBZ rather than penetration is desirable considering the
intended use of the active; nevertheless, the underlying reasons for the
preferential deposition of CBZ in the outer skin layers deserve further
investigation.
Skin delivery of CBZ was examined from four solvents under ﬁnite
and inﬁnite dose conditions. The results conﬁrm, once again, the need
to interpret ﬁndings from inﬁnite dose experiments with caution when
developing topical formulations of actives. For inﬁnite dose studies
lower amounts of CBZ were recovered following skin extraction, when
compared to ﬁnite dose studies. DVS studies on the various formula-
tions also simulated the “drying down” or metamorphosis that occurs
following application of ﬁnite doses of topical preparations to the skin
and have also not been reported previously for CBZ. PG and OSal ap-
pear promising candidate vehicles for CBZ and should be considered as
components of more complex formulations or binary systems.
Although porcine ear skin is widely accepted as a useful surrogate
for human skin, signiﬁcantly higher amounts of CBZ were extracted
from the former compared with the latter. This likely reﬂects diﬀer-
ences in morphology and composition of the tissues but again also
points to speciﬁc interactions of CBZ with skin that vary depending on
the membrane selected for study. Future work will expand the range of
vehicles examined using ﬁnite dose studies in human skin with the
ultimate objective of achieving concentrations that approximate the
MIC required for Malassezia spp in the skin. More permeation studies
focusing on the penetration of solvents, as well as keratin binding
studies may also shed light to the reason behind the low permeability of
CBZ.
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Fig. A.1. Stability of 1% CBZ formulations in PG, PEG 200, TC, OSal and 0.01% in PBS over a 4 day period. n= 3, mean ± SD.
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